Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

2023423 citationsJournal Article

Authors

Myung‐Ju Ahn · Hebron University

Byoung Chul Cho · Hebron University

Enriqueta Felip · Hebron University

Ippokratis Korantzis · Hebron University

Kadoaki Ohashi · Hebron University

Margarita Majem · Hebron University

Óscar Juan ·

Abstract

Tarlatamab, administered as a 10-mg dose every 2 weeks, showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. No new safety signals were identified. (Funded by Amgen; DeLLphi-301 ClinicalTrials.gov number, NCT05060016.).

Topics & Keywords

Lung Cancer Research Studies Neuroendocrine Tumor Research Advances Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 389, Issue 22, pp. 2063-2075

DOI: 10.1056/nejmoa2307980

Field-Weighted Citation Impact: 96.93